drugset / Trial / NCT02906722

Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia

NCT02906722

Phase 3 Terminated 7 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupDouble-blindTreatment

Summary

Few antimicrobials are available to treat ventilated associated pneumonia (VAP) caused by Gram negative multi-resistant (MDR) bacteria. Colimycin often remains the only active antibiotic. The aim of the study is to demonstrate the superiority of nebulized colimycin over intravenous colimycin to treat VAP caused by Gramnegative MDR bacteria.

Timeline

Start
2017-07-31
Primary completion
2018-03-27
Completion
2018-06-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colistin Other / unclassified Intravenous

Indications

No indication recorded.